Cancer biotech Kura Oncology files for an $86 million IPO
Kura Oncology, which is developing treatments of various cancers based on molecular biomarkers, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering.
The La Jolla, CA-based company, which was founded in 2014, plans to list on the Nasdaq under the symbol KURA. Citi and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Cancer biotech Kura Oncology files for an $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.